Decision Making Among Older Adults: the AUTO Study
Sponsor:University of Colorado, DenverBrief Summary: This Stage II randomized, controlled, longitudinal trial seeks to assess the acceptability, feasibility, and effects…
[searchandfilter fields="search,category" post_types="post"]
A Randomized, Double-Blind, Placebo-Controlled, Two-Part Study in Parkinson’s Disease Patients With Dyskinesia to Assess the Efficacy and Safety/Tolerability of Fixed Dose Combinations of JM-010 and Its Individual Components
Sponsor:Bukwang PharmaceuticalBrief Summary: This is a two-part, double-blind, placebo-controlled, randomized, multicenter Phase 2 clinical trial of JM-010 in patients with…
A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Parkinson’s Disease
Sponsor:ProgenaBiomeBrief Summary: This study seeks to correlate microbiome sequencing data with information provided by patients and their medical records regarding…
A Randomized, Double-Blind, Double-Dummy, Active-Controlled Study Comparing the Efficacy, Safety and Tolerability of ABBV-951 to Oral Carbidopa/Levodopa in Advanced Parkinson’s Disease Patients
Sponsor:AbbVieBrief Summary: Parkinson's disease (PD) is a neurological condition, which affects the brain. PD gets worse over time, but how…
A Study to Evaluate NYX-458 in Subjects With Mild Cognitive Impairment Associated With Parkinson’s Disease
Sponsor:AptinyxBrief Summary: To evaluate the safety and tolerability of NYX-458 in mild cognitive impairments associated with Parkinson's disease and explore…
Evaluating the Effectiveness of an Online Small-Group Self-Management Workshop for Rural Caregivers of Individuals With Alzheimer’s Disease and Related Dementias
Sponsor:University of California, San FranciscoBrief Summary: These caregivers are a vulnerable group due to their physical isolation and well-documented rural…
Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of 36 Weeks of Treatment With NLY01 in Early-stage Parkinson’s Disease
Sponsor:Neuraly, Inc.Brief Summary: This is a phase 2 study designed to assess the safety, tolerability and efficacy of NLY01 in…
Mindfulness-based Cognitive Therapy for People With Parkinson’s Disease and Caregivers
Sponsor:University of California, San FranciscoBrief Summary: This study aims to explore the feasibility and effectiveness of mindfulness-based cognitive therapy (MBCT)…
A Pilot Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety and Daytime Sedation in Subjects With Parkinson’s Disease With Neuropsychiatric Symptoms Treated With Pimavanserin or Low-Dose Quetiapine
Sponsor:ACADIA Pharmaceuticals Inc.Brief Summary: This is a pilot, hypothesis-generating study to explore the effects of pimavanserin and low-dose quetiapine in…
An Open-Label Evaluation of the Safety and Tolerability of SAGE-718 in Participants With Parkinson’s Disease Mild Cognitive Impairment
Sponsor:Sage TherapeuticsBrief Summary: The primary purpose of this study is to evaluate the safety and tolerability of SAGE-718 and its…
